CGEM Overview
Upcoming Projects (CGEM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CGEM)
-
Discussing the results from the pivotal Phase 2b REZILIENT1 trial evaluating zipalertinib in patients with EGFR Exon 20 insertion mutation–positive non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
Tickers: TAIHO PHARMACEUTICAL, CGEM
Executed On: Jun 16, 2025 at 01:15 PM EDT
Upcoming & Overdue Catalysts (CGEM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CGEM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
